The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk
| Status: | Completed |
|---|---|
| Conditions: | Peripheral Vascular Disease, Infectious Disease, HIV / AIDS |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 40 - 80 |
| Updated: | 7/11/2015 |
| Start Date: | April 2010 |
| End Date: | December 2014 |
| Contact: | Priscilla Hsue, MD |
| Email: | phsue@medsfgh.ucsf.edu |
| Phone: | 4152068257 |
It is the central hypothesis of the investigators study that HIV disease is a
pro-inflammatory condition, and that years of inflammation result in premature "aging' of
the immune system ("immunosenescence"). Just as these changes are thought be causally
associated with heart disease in the very old,the investigators postulate that these changes
will be associated with early heart disease in the untreated and perhaps treated HIV
disease. To address this hypothesis, the investigators will measure immunosenescence in a
large cohort of patients who span the entire disease process.
pro-inflammatory condition, and that years of inflammation result in premature "aging' of
the immune system ("immunosenescence"). Just as these changes are thought be causally
associated with heart disease in the very old,the investigators postulate that these changes
will be associated with early heart disease in the untreated and perhaps treated HIV
disease. To address this hypothesis, the investigators will measure immunosenescence in a
large cohort of patients who span the entire disease process.
Inclusion Criteria:
- HIV controllers: positive for HIV by standard antibody serological determinations
with undetectable HIV RNA level (< 75 copies RNA/mL) in absence of therapy
- HIV non-controllers: detectable HIV RNA levels in absence of therapy
- Highly active anti-retroviral therapy responders (HAART responders): on combination
antiretroviral therapy with undetectable HIV RNA levels.
- HIV-seronegative participants will also be studied.
Exclusion Criteria:
- Treated individuals that changed antiretroviral regimen within 12 weeks prior to
study enrollment.
- Individuals who have started or stopped antihypertensive medication or lipid lowering
medication or changed doses of these drugs within 12 weeks of the study will be
excluded.
- As nitroglycerin is administered to assess endothelium-independent vasodilation, we
also plan to exclude patients who have taken sildenafil, vardenafil, or tadalafil
within 72 hours of the endothelial function study, or who are hypotensive (systolic
BP <100).
We found this trial at
1
site
533 Parnassus Ave
San Francisco, California 94122
San Francisco, California 94122
(415) 476-9000
University of California - San Francisco The leading university exclusively focused on health, UC San...
Click here to add this to my saved trials
